1-5 of 5
Judit Mészáros Joergensen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Lorenzo Falchi, Fabrice Jardin, Corinne Haioun, Tomasz Wrobel, Judit Mészáros Joergensen, Mariana Bastos-Oreiro, Eric Mou, Joaquin Martinez-Lopez, L. Elizabeth Budde, Nancy L. Bartlett, Jan M. Zaucha, Alejandro Martin Garcia-Sancho, Rutanshu Shah, Nathan Rees, Ron McCord, Alexandra Bazeos, Maneesh Tandon, Michelle Doral, Ethan Troy-Barnes, Marcel Nijland
Journal: Blood
Blood (2023) 142 (Supplement 1): 858.
https://doi.org/10.1182/blood-2023-173953
Published: 2023
Journal Articles

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Joshua Brody, Judit Mészáros Joergensen, David Belada, Regis T. Costello, Marek Trněný, Umberto Vitolo, David Lewis, Yasmin H. Karimi, Anna Maria Sureda Balari, Marc André, Björn E. Wahlin, Pieternella Lugtenburg, Faith Galderisi, Aqeel Abbas, Yaou Song, Malene Risum, Raul Cordoba
Journal: Blood
Blood (2023) 142 (Supplement 1): 3092.
https://doi.org/10.1182/blood-2023-180246
Published: 2023
Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Martin Hutchings, Abraham Avigdor, Anna Maria Sureda Balari, Maria José Terol, Francesc Bosch, Paolo Corradini, Thomas S. Larsen, Antonio Rueda Dominguez, Alan Skarbnik, Judit Mészáros Joergensen, David Lavie, Ronit Gurion, Pier Luigi Zinzani, Antonio Pinto, Raul Cordoba, Alessia Bottos, Donghang Li, James Relf, Audrey Filézac De L'Étang, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2023) 142 (Supplement 1): 4460.
https://doi.org/10.1182/blood-2023-174213
Published: 2023
Journal Articles

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Julio C. Chavez, Loretta J. Nastoupil, Franck Morschhauser, Guillaume Cartron, Judit Mészáros Joergensen, Emmanuel Bachy, Pierre Bories, Victoria Campbell, Bijou Fontanet, Poliana P. Patah, Bérengère de Moucheron, Soraya Carrancio, Xirong Zheng, Chaoqun Mei, Michael Pourdehnad, Jean-Marie Michot
Journal: Blood
Blood (2023) 142 (Supplement 1): 4496.
https://doi.org/10.1182/blood-2023-188771
Published: 2023
Journal Articles

Differences in Overall Survival for Non-Western Immigrant Patients Compared to Danish-Born Patients with Diffuse Large B-Cell Lymphoma

Mikkel Runason Simonsen, Lasse Hjort Jakobsen, Marianne Tang Severinsen, Henrik Frederiksen, Carsten Utoft Niemann, Judit Mészáros Joergensen, Michael Roost Clausen, Jørn Starklint, Søren Paaske Johnsen, Tarec Christoffer El-galaly, Joachim Baech
Journal: Blood
Blood (2023) 142 (Supplement 1): 6257.
https://doi.org/10.1182/blood-2023-179786
Published: 2023